| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514160800 | Osteoarthritis | 28 |
| 20100267639 | TREATMENT OF OSTEOARTHRITIS - This invention relates to methods of treatment of osteoarthritis, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes and macrophages. Particularly preferred compounds for use in the invention are disclosed. | 10-21-2010 |
| 20100292154 | PROTEIN PROFILE FOR OSTEOARTHRITIS - The present invention relates to the identification and use of protein expression profiles with clinical relevance to osteoarthritis (OA). In particular, the invention provides the identity of marker proteins whose expression is correlated with OA and OA progression. Methods and kits are described for using these protein expression profiles in the study and/or diagnosis of OA, in the determination of the degree of advancement of OA, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that modulate expression of these proteins or nucleic acid molecules encoding these proteins, in particular for the development of disease-modifying OA agents. | 11-18-2010 |
| 20100292155 | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides - The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides. | 11-18-2010 |
| 20100292156 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF - Disclosed are pharmaceutical compositions containing, as the active ingredients, a mixture of a hyaluronic acid polymer with a bradykinin B2 receptor antagonist. Said compositions have proved especially effective in the treatment of degenerative joint diseases such as osteoarthritis using intra-articular injections. | 11-18-2010 |
| 20100317588 | COMPOSITIONS COMPRISING FIBROUS POLYPEPTIDES AND POLYSACCHARIDES - Isolated polypeptides are disclosed comprising an amino acid sequence encoding a monomer of a fibrous polypeptide attached to a heterologous polysaccharide binding domain. Composites comprising same, methods of generating same and uses thereof are all disclosed. | 12-16-2010 |
| 20110195906 | OSTEOGENIC SYNTHETIC PEPTIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND MEDIUM CONTAINING THE SAME - Disclosed herein is an osteogenic synthetic peptide, derived from bone morphogenetic protein-7, consisting of a sequence of 15 amino acid residues. Provided are also a pharmaceutical composition and a medium composition comprising the same. Having remarkable activity related to promoting osteoblast differentiation, the osteogenic synthetic peptide is very useful in the treatment of osteoporosis, bone defects and/or osteoarthritis. | 08-11-2011 |
| 20110251131 | DEUTERATED 2-AMINO-3-HYDROXYPROPANOIC ACID DERIVATIVES - This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an NMDA glycine-site antagonist. | 10-13-2011 |
| 20110288024 | Compositions and Methods for Treating Arthritis and/or Diseases Involving Cartilage Degeneration - The invention provides pharmaceutical polypeptide compositions that promote proteoglycan synthesis, and promote the activity of chondrocyte cells, thereby treating arthritis. Methods of providing these compositions to treat arthritis are also provided. | 11-24-2011 |
| 20120202744 | DUAL ANTAGONISM OF ENDOTHELIN TYPE A AND BRADYKININ B1 RECEPTORS FOR TREATING PAIN AND PREVENTING CARTILAGE DEGRADATION - The present invention relates to the field of anatomy, and more particularly to the control of pain and to the prevention and treatment of osteoarthritic cartilage degradation. Described herein are methods for treating pain which comprise administering to a subject in need a combination of (i) an antagonist of the endothelin type A receptor (ETA) and (ii) an antagonist of the bradykinin B1 receptor (BKB1). Also described are methods for preventing osteoarthritic cartilage degradation and pharmaceutical compositions for treating pain, for preventing osteoarthritic cartilage degradation, and/or for preventing osteoarthritic joint inflammation, in subjects. | 08-09-2012 |
| 20120277157 | DISEASE TREATMENT VIA ANTIMICROBIAL PEPTIDES OR THEIR INHIBITORS - Provided are methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. Also provided are specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease. | 11-01-2012 |
| 20130090292 | TREATMENT OF DEGENERATIVE JOINT DISEASE - The invention provides a method of treating a degenerative joint disease. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a pharmaceutical product as well as a kit comprising DA-DKP. | 04-11-2013 |
| 20130137639 | STABLE MIA/CD-RAP FORMULATION - The present invention relates to stable aqueous formulations comprising at least 5 mg/mL CD-RAP and a charged amino acid, said amino acid preferably having a net charge at a pH between about 6 and 8. The ingredients of the formulation preferably provide stability over repeated freeze-thaw cycles. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory disorders, preferably osteoarthritis. Furthermore, a kit comprising the formulation of the invention is provided. | 05-30-2013 |
| 20130165383 | APO-2 LIGAND/TRAIL VARIANTS AND USES THEREOF - The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided. | 06-27-2013 |
| 20130178425 | METHODS AND COMPOSITIONS FOR DELIVERING INTERLEUKIN-1 RECEPTOR ANTAGONIST - Methods, systems, and compositions related to generating and using a solution rich in interleukin-1 receptor antagonist are provided. Methods include contacting a liquid comprising white blood cells with a solid extraction material and stimulating with an electromagnetic field to activate production of interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist can be separated from the solid extraction material. Methods for treating a site of inflammation in a patient include administering the solution rich in interleukin-1 receptor antagonist to the site of inflammation. | 07-11-2013 |
| 20130288972 | Compositions and Methods For The Treatment of Orthopedic Disease or Injury - Methods for reducing the severity of an arthritic condition or repairing an osteochondral defect are carried out by administering to a subject compositions comprising a member of the matrilin family of proteins, e.g., a matrilin protein, fragment thereof, or nucleic acid encoding the protein or fragment. | 10-31-2013 |
| 20140024596 | DISEASE INHIBITING AGENT - At least one peptide molecule selected from EGDGHLGKPGROGE (SEQ ID NO:1), EKDGHPGKPGROGE (SEQ ID NO:2), G(POG) | 01-23-2014 |
| 20140213523 | BIGLYCAN VARIANT POLYPEPTIDES AND METHODS OF USE - The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include Amyotrophic Lateral Sclerosis (ALS), as well as muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. | 07-31-2014 |
| 20140256642 | TREATMENT OF DEGENERATIVE JOINT DISEASE - The invention provides a method of treating a degenerative joint disease. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a pharmaceutical product as well as a kit comprising DA-DKP. | 09-11-2014 |
| 20140364371 | DIRECT DRUG DELIVERY SYSTEM BASED ON THERMALLY RESPONSIVE BIOPOLYMERS - A method for delivering a drug depot of a compound of interest to a selected region in a subject. The method comprises administering a composition directly to said region of interest, the composition comprising the compound of interest to be delivered (such as an antiinflammatory agent or a chemotherapeutic agent) and a polymer (such as an elastin-like peptide or ELP) that undergoes an inverse temperature phase transition, so that a sustained release of the compound of interest at the selected region is provided. Compositions useful for carrying out the invention are also described. | 12-11-2014 |
| 20150018279 | COMPOSITIONS AND METHODS FOR DELIVERY OF KINASE INHIBITING PEPTIDES - The invention relates to compositions and methods for the treatment of inflammatory disease states. In particular, the invention relates to the use of a nanoparticle incorporated kinase inhibiting peptide to treat inflammatory disease states. | 01-15-2015 |
| 20150057229 | METHOD OF TREATING BONE DISORDERS USING TSG-6 - A method for inhibiting cartilage degradation comprising administering to a subject a therapeutically effective amount of a polypeptide comprising or consisting of a Link_TSG6 polypeptide is disclosed | 02-26-2015 |
| 20150065427 | MODULATION OF OSTEOCLAST DIFFERENTIATION - Provided are methods for treating a pathological condition associated with unbalanced osteoclast differentiation by providing an AQP-9 modulator. The modulator can be an AQP-9 inhibitor or an AQP-9 inducer. Also provided are methods for modulating osteoclast differentiation, methods for treating pathological conditions associated with unbalanced osteoclast differentiation, as well as pharmaceutical composition including such modulators. | 03-05-2015 |
| 20150352175 | TREATMENT OF DEGENERATIVE JOINT DISEASE - The invention provides a method of treating a degenerative joint disease. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a pharmaceutical product as well as a kit comprising DA-DKP. | 12-10-2015 |
| 20160045493 | TREATMENT OF JOINT CONDITIONS - The invention provides a method of treating a joint condition. The method comprises administering a multi-dose regimen of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a method of treating osteoarthritis with multiple doses of a low-molecular weight fraction of human serum albumin. | 02-18-2016 |
| 20160074429 | Low-Molecular-Weight Biotechnological Chondroitin 6-Sulphate for Prevention of Osteoarthritis - Disclosed is a low-molecular-weight (1000-5000 daltons) chondroitin sulphate (CS) produced by chemical sulphation and subsequent depolymerisation of a non-sulphated chondroitin backbone obtained with biotechnology techniques. The CS described is substantially monosulphated, mainly at the 6-position, with very little sulphation at the 4-position, and with a mono/disulphated disaccharide ratio and charge density similar to those of natural CS. Said biotechnological chondroitin 6-sulphate (C6S) is useful in the treatment and prevention of osteoarthritis and in acute and chronic inflammatory processes. | 03-17-2016 |
| 20160129076 | EXTRACELLULAR MATRIX-BINDING SYNTHETIC PEPTIDOGLYCANS - This disclosure provides extracellular matrix-binding synthetic peptidoglycans comprised of one or more synthetic peptides conjugated to a glycan and methods of their use. | 05-12-2016 |
| 20160158270 | BIOMATERIALS COMPRISING HYALURONIC ACID BINDING PEPTIDES AND EXTRACELLULAR MATRIX BINDING PEPTIDES FOR HYALURONIC ACID RETENTION AND TISSUE ENGINEERING APPLICATIONS - The present invention provides novel biomaterial compositions and methods having a technology to improve retention of hyaluronic acid (HA). The biomaterial compositions utilize small HA binding peptides and extracellular matrix binding (ECM) peptides that are tethered to synthetic biocompatible polymers. When tethered to the polymers, the peptide region allows the polymers to bind to HA and to tissues such as cartilage. The novel biomaterial compositions can be used to coat or chemically modify cartilage or tissues with a biologically compatible polymer having HA binding peptides, which allow HA to bind to the surface of the cartilage or tissues. Methods of using same are also provided. | 06-09-2016 |
| 20160250286 | CONTROL OF RHEOLOGICAL PROPERTIES OF MIXED HYALURONATE/LUBRICIN SOLUTIONS | 09-01-2016 |
